QUANTIFYING THE SOCIETAL VALUE OF RESMETIROM FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS USING A SOCIETAL VALUE MODELING APPROACH
Author(s)
Thomas Flottemesch, PhD1, Marlon Graf, MPP, PhD1, Iris Brewer, MS1, Amal Jamaleddine, MSc1, James Baumgardner, PhD1, Jacki Chou, MPP1, Yestle Kim, MSc, PharmD2, Nipun Atreja, MS, PhD2.
1Precision AQ, Bethesda, MD, USA, 2Madrigal Pharmaceuticals, West Conshohocken, PA, USA.
1Precision AQ, Bethesda, MD, USA, 2Madrigal Pharmaceuticals, West Conshohocken, PA, USA.
OBJECTIVES: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with metabolic risk factors and contributes to significant morbidity, mortality, and healthcare costs. Until recently, treatment was limited to lifestyle modification with modest effectiveness. Conditional approval of resmetirom, a thyroid hormone receptor-β agonist, represents the first pharmacologic therapy specifically indicated for MASH in the US and Europe. While its efficacy has been evaluated in clinical trials, broader societal impacts remain underexplored. In this study, we quantify the societal value of resmetirom.
METHODS: We developed a societal value model informed by outputs from an existing Markov transition state cost-effectiveness analysis of resmetirom in the United States. The model population includes individuals with noncirrhotic MASH and moderate to advanced liver fibrosis. We included productivity, caregiver burden, and manufacturer reinvestment in our societal value calculation. Monetized quality-adjusted life year (QALY) gains were used to estimate total societal value, which was then apportioned to patients, manufacturers, and broader society.
RESULTS: Between 2024 and 2053 (a 30-year lifecycle), an estimated 3 million persons initiate resmetirom, resulting in 1.7 million QALYs saved (QALYS). After applying the value of a QALY, these QALYS translate to $123 billion in direct societal value. We further estimate $96 billion in indirect societal value due to increased patient productivity ($63 billion) and reduced caregiver burden ($33 billion) as well as $5 billion from manufacturer reinvestment at a risk-neutral return. This results in a total of $224 billion in societal value during resmetirom’s initial 30-year product lifecycle. Of this, $161 billion (72%) accrued as consumer surplus while $61 billion (27%) represented the manufacturer share. The remaining $2 billion (1%) is accrued to others in the economy.
CONCLUSIONS: In the context of emerging therapies for MASH, resmetirom’s societal value reflects not only clinical benefits but also broader economic and societal gains.
METHODS: We developed a societal value model informed by outputs from an existing Markov transition state cost-effectiveness analysis of resmetirom in the United States. The model population includes individuals with noncirrhotic MASH and moderate to advanced liver fibrosis. We included productivity, caregiver burden, and manufacturer reinvestment in our societal value calculation. Monetized quality-adjusted life year (QALY) gains were used to estimate total societal value, which was then apportioned to patients, manufacturers, and broader society.
RESULTS: Between 2024 and 2053 (a 30-year lifecycle), an estimated 3 million persons initiate resmetirom, resulting in 1.7 million QALYs saved (QALYS). After applying the value of a QALY, these QALYS translate to $123 billion in direct societal value. We further estimate $96 billion in indirect societal value due to increased patient productivity ($63 billion) and reduced caregiver burden ($33 billion) as well as $5 billion from manufacturer reinvestment at a risk-neutral return. This results in a total of $224 billion in societal value during resmetirom’s initial 30-year product lifecycle. Of this, $161 billion (72%) accrued as consumer surplus while $61 billion (27%) represented the manufacturer share. The remaining $2 billion (1%) is accrued to others in the economy.
CONCLUSIONS: In the context of emerging therapies for MASH, resmetirom’s societal value reflects not only clinical benefits but also broader economic and societal gains.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE333
Topic
Economic Evaluation
Topic Subcategory
Novel & Social Elements of Value
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas